Detalhe da pesquisa
1.
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Ann Rheum Dis
; 82(7): 937-944, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36958796
2.
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.
Ann Rheum Dis
; 79(9): 1243-1249, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32581088
3.
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.
Trials
; 24(1): 180, 2023 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906660
4.
Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Trials
; 18(1): 112, 2017 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28270229